These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 17420404)

  • 1. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.
    Rabinovici GD; Furst AJ; O'Neil JP; Racine CA; Mormino EC; Baker SL; Chetty S; Patel P; Pagliaro TA; Klunk WE; Mathis CA; Rosen HJ; Miller BL; Jagust WJ
    Neurology; 2007 Apr; 68(15):1205-12. PubMed ID: 17420404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients.
    Rostomian AH; Madison C; Rabinovici GD; Jagust WJ
    J Nucl Med; 2011 Feb; 52(2):173-9. PubMed ID: 21233181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Accuracy of Amyloid versus
    Lesman-Segev OH; La Joie R; Iaccarino L; Lobach I; Rosen HJ; Seo SW; Janabi M; Baker SL; Edwards L; Pham J; Olichney J; Boxer A; Huang E; Gorno-Tempini M; DeCarli C; Hepker M; Hwang JL; Miller BL; Spina S; Grinberg LT; Seeley WW; Jagust WJ; Rabinovici GD
    Ann Neurol; 2021 Feb; 89(2):389-401. PubMed ID: 33219525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.
    Rabinovici GD; Rosen HJ; Alkalay A; Kornak J; Furst AJ; Agarwal N; Mormino EC; O'Neil JP; Janabi M; Karydas A; Growdon ME; Jang JY; Huang EJ; Dearmond SJ; Trojanowski JQ; Grinberg LT; Gorno-Tempini ML; Seeley WW; Miller BL; Jagust WJ
    Neurology; 2011 Dec; 77(23):2034-42. PubMed ID: 22131541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
    Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
    Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
    Rowe CC; Ackerman U; Browne W; Mulligan R; Pike KL; O'Keefe G; Tochon-Danguy H; Chan G; Berlangieri SU; Jones G; Dickinson-Rowe KL; Kung HP; Zhang W; Kung MP; Skovronsky D; Dyrks T; Holl G; Krause S; Friebe M; Lehman L; Lindemann S; Dinkelborg LM; Masters CL; Villemagne VL
    Lancet Neurol; 2008 Feb; 7(2):129-35. PubMed ID: 18191617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
    Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
    Womack KB; Diaz-Arrastia R; Aizenstein HJ; Arnold SE; Barbas NR; Boeve BF; Clark CM; DeCarli CS; Jagust WJ; Leverenz JB; Peskind ER; Turner RS; Zamrini EY; Heidebrink JL; Burke JR; DeKosky ST; Farlow MR; Gabel MJ; Higdon R; Kawas CH; Koeppe RA; Lipton AM; Foster NL
    Arch Neurol; 2011 Mar; 68(3):329-37. PubMed ID: 21059987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of molecular imaging on the diagnostic process in a memory clinic.
    Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
    Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
    J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
    Banzo I; Jiménez-Bonilla J; Ortega-Nava F; Quirce R; Martínez-Rodríguez I; de Arcocha-Torres M; Rodríguez E; Vázquez JL; Sánchez PJ; Martínez-Amador N; Ibañez-Bravo S; Carril JM
    Nucl Med Commun; 2014 Mar; 35(3):238-44. PubMed ID: 24240196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.
    Snellman A; López-Picón FR; Rokka J; Salmona M; Forloni G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    J Nucl Med; 2013 Aug; 54(8):1434-41. PubMed ID: 23833271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
    Taswell C; Villemagne VL; Yates P; Shimada H; Leyton CE; Ballard KJ; Piguet O; Burrell JR; Hodges JR; Rowe CC
    J Nucl Med; 2015 Oct; 56(10):1547-53. PubMed ID: 26251415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.